[go: up one dir, main page]

WO1992008474A3 - Treatment of lung diseases - Google Patents

Treatment of lung diseases Download PDF

Info

Publication number
WO1992008474A3
WO1992008474A3 PCT/GB1991/002049 GB9102049W WO9208474A3 WO 1992008474 A3 WO1992008474 A3 WO 1992008474A3 GB 9102049 W GB9102049 W GB 9102049W WO 9208474 A3 WO9208474 A3 WO 9208474A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
provides
cyclosporin
corticosteroids
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1991/002049
Other languages
French (fr)
Other versions
WO1992008474A2 (en
Inventor
Anthony Barry Kay
Neil Christopher Barnes
Peter John Cole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Heart and Lung Institute
Original Assignee
National Heart and Lung Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909025154A external-priority patent/GB9025154D0/en
Application filed by National Heart and Lung Institute filed Critical National Heart and Lung Institute
Publication of WO1992008474A2 publication Critical patent/WO1992008474A2/en
Publication of WO1992008474A3 publication Critical patent/WO1992008474A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Specific pharmacological targeting of T-lymphocytes provides a new approach to the treatment of chronic asthma (both in patients relatively sensitive and resistant to the effects of corticosteroids) and to the treatment of other lung deseases such as bronchiectasis and cystic fibrosis, as well as sinusitis. The invention provides the use of cyclosporin A and other immunosuppressive agents with the same or similar mode or site of action for the treatment of diseases characterised by airflow obstruction and/or of chronic sinusitis. Suitable other agents include FK 506, rapamycin and humanised anti-CD4 antibodies. The invention also provides an in vitro test for prediction of clinical response to corticosteroids and immunosuppressive agents. Corticosteroid resistance can be identified by the in vitro test and corticosteroid-resistant patients thus identified can be treated by cyclosporin A or other suitable immunosuppressive agent.
PCT/GB1991/002049 1990-11-20 1991-11-20 Treatment of lung diseases Ceased WO1992008474A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909025154A GB9025154D0 (en) 1990-11-20 1990-11-20 Treatment of lung diseases
GB9025154.7 1990-11-20
GB9026620.6 1990-12-07
GB909026620A GB9026620D0 (en) 1990-11-20 1990-12-07 Treatment of lung diseases

Publications (2)

Publication Number Publication Date
WO1992008474A2 WO1992008474A2 (en) 1992-05-29
WO1992008474A3 true WO1992008474A3 (en) 1992-06-25

Family

ID=26297977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/002049 Ceased WO1992008474A2 (en) 1990-11-20 1991-11-20 Treatment of lung diseases

Country Status (2)

Country Link
AU (1) AU8910891A (en)
WO (1) WO1992008474A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
DE69312077T2 (en) * 1992-10-08 1997-10-30 Kennedy Inst Of Rheumatology TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES
US5707622A (en) * 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5874080A (en) * 1994-03-03 1999-02-23 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of asthma
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
ES2206590T3 (en) * 1995-09-19 2004-05-16 Fujisawa Pharmaceutical Co., Ltd. AEROSOL COMPOSITIONS.
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
EP1100495A4 (en) * 1998-07-28 2002-09-25 Smithkline Beecham Corp Propenamides as ccr5 modulators
GB9818278D0 (en) * 1998-08-22 1998-10-14 Smith & Nephew Compositions
JP2002538170A (en) * 1999-03-02 2002-11-12 セントコール， インコーポレイテッド Anti-TNFα antibodies in the treatment of asthma
JP2006517217A (en) * 2003-02-10 2006-07-20 ノバルティス アクチエンゲゼルシャフト Pharmaceutical combination comprising a corticoid and an immunosuppressant for treating a corticoid and / or calcineurin inhibitor resistant disease
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005030252A1 (en) * 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Treatment of respiratory diseases with anti-il-2 receptor antibodies
WO2005063242A1 (en) * 2003-12-30 2005-07-14 Astellas Pharma Inc. Use of macrolides for treating or preventing airflow obstruction
EP1874118A4 (en) * 2005-04-27 2009-07-22 Univ Florida MATERIALS AND METHODS FOR IMPROVING THE DEGRADATION OF MUTANT PROTEINS ASSOCIATED WITH A HUMAN DISEASE
CA2638774C (en) 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
TWI434854B (en) 2007-11-13 2014-04-21 Evec Inc Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Dialog Information Services, file 155, Medline, 66- 92, Dialog Accession No. 06229897, Lagrue G. et al.: "Membranoproliferative glomerulonephritis assosiciated with Buckley's syndrome treated with cyclosporin. Glomerulonephrite membrano-proliferative associee a un syndrome de Buckley traitee par la ciclosporine", & Presse Med Apr 11 1987, 16 (13) p619-21 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07458632, Fukuda T.: "Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin A", & Arerugi May 1990, & Arerugi May 1990, 39 (5) p483-7 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07590095, Fukuda T. et al: "The role of eosinophils, neutrophils and lymphocytes for the development of bronchial hyperresponsiveness in a guinea pig model of asthma", & Nippon Kyobu Shikkan Gakkai Zasshi Oct 1990, 28 (10)p128 8-93 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07858952, Szczeklik A. et al: "Cyclosporin for steroid-dependentasth ma", & Allergy May 1991, 46 (4) p312-5 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07902257, Fukuda T. et al: "Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506", & Int Arch Allergy Appl Immunol (SWITZERLAND) 1991, 94 (1-4) p259-61 *
Dialog Information Services, file 5, BIOSIS, 69-92, Dialog Accession No. 4856115, Pedersen C. et al.: "Inhibitory effect of cyclosporin A on histamine release from human leukocytes and rat mast cells", & Allergy (COPENH) 40 (2), 1985, 103-107 *
Dialog Information Services, file 5, BIOSIS, 69-92, Dialog Accession No. 7905334, Finnerty N.A. et al.: "Effect of cyclosporine on corticosteroid dependent asthma", & J Allergy Clin Immunol 87 (1 part 2), 1991, 297 *

Also Published As

Publication number Publication date
WO1992008474A2 (en) 1992-05-29
AU8910891A (en) 1992-06-11

Similar Documents

Publication Publication Date Title
WO1992008474A3 (en) Treatment of lung diseases
Epstein et al. Time course of hemosiderin production by alveolar macrophages in a murine model
Wardlaw et al. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.
US5837713A (en) Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
Ip et al. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty
JP3434824B2 (en) Immunosuppressants and antiallergic compounds such as N- (3-oxyhexanoyl) homoserine lactone
Fujisawa et al. The neutrophil and chronic allergic inflammation
ITMI912296A0 (en) NEW PREGNA 1,4-DIENE-3,20.DIONE-16,17-ACETAL-21-ESTERS, PROCEDURE FOR THEIR PREPARATION, COMPOSITION AND METHODS FOR THE TREATMENT OF INFLAMMATORY STATES
Paolieri et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines
AP2000001805A0 (en) Use of antifungal agents for the topical treatment of fungus-induced mucositis.
WO2005099776A3 (en) Steroid sparing agents and methods of using same
RU2004123463A (en) Steroid sapogenins and their derivatives for the treatment of diseases
CY2009010I1 (en) METHOD FOR ENRICHMENT OF R-EPIMER OF 16,17-ACETAL DERIVATIVES OF 21-ACYLOXY PREGNA-1,4-DIEN-11.BETA., 16.ALPHA., 17.ALPHA.-TRIOL-3,20-DIONE
BR9811823A (en) Method and compositions for treating late-stage allergic reactions and inflammatory diseases
Patella et al. Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells.
Moqbel et al. The effect of platelet-activating factor on IgE binding to, and IgE-dependent biological properties of, human eosinophils
Dalakas The role of high-dose immune globulin intravenous in the treatment of dermatomyositis
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
WO2001082953A3 (en) Methods for treatment of diseases associated with inflammation under non-ischemic conditions
Säwe et al. Glucuronidation of morphine in human liver and interaction with oxazepam
Mehindate et al. Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast-like synoviocytes. Differential regulation by interleukin-4 and dexamethasone.
Skowron et al. Alternating and intermittent regimens of zidovudine (3′-azido-3′-deoxythymidine) and dideoxycytidine (2′, 3′-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex
Muhlfelder et al. Glucocorticoids inhibit the generation of leukocyte procoagulant (tissue factor) activity
AU2703297A (en) New derivatives of pregnane with no substituent in position 17-alpha, their use as medicaments, their preparation process, the intermediates of this process and the compositions containing them
Briggs et al. Plasma lipoprotein changes during oral contraception

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA